Evidence map›Paper›PMID 35513496›Full record

ReviewSeminars in immunopathology2022

Glial-mediated neuroinflammatory mechanisms in age-related macular degeneration.

Rahul M Dhodapkar, Diego Martell, Brian P Hafler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Seminars in immunopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Effects of Fucoidans on Activated Retinal Microglia.International journal of molecular sciences · 2024
    Article
  9. Article
  10. Innate immune biology in age-related macular degeneration.Frontiers in cell and developmental biology · 2023
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rahul M DhodapkarYale School of Medicine, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2014-7515
Diego MartellDepartment of Ophthalmology and Visual Science, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-8839-1864
Brian P HaflerDepartment of Ophthalmology and Visual Science, Yale University, New Haven, CT, USA. brian.hafler@yale.edu.ORCID http://orcid.org/0000-0002-9263-3037
Yale University · US

Funding

Doris Duke Charitable Foundation Clinical Scientist Development Award
6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is a neurodegenerative disorder characterized by photoreceptor and retinal pigment epithelium loss often complicated by neovascularization and is one of the leading causes of irreversible vision loss worldwide. However, the precise pathophysiology of AMD remains to date unclear, and there is a dearth of effective therapies for the early stages of the disease. A growing body of evidence has identified microglia-mediated neuroinflammation as a key driver of neuronal damage in AMD, presenting a novel avenue for the development of pharmacological agents targeting this cell population. The local microglial response interacts with other glia as well as engages in crosstalk with peripheral immunological niches. This article presents a review of the current evidence regarding the involvement of glia in the pathophysiology of AMD, an overview of the key immune circuits and effector mechanisms shown to be active in AMD, and potential therapeutic avenues targeting glial involvement.

Indexed as

Macular DegenerationHumansMicrogliaNeurogliaRetinal Pigment EpitheliumAge-related macular degenerationGlia-glia interactionsGlia-neuron interactionsNeurodegenerationNeuroinflammation

Identifiers

PMID35513496
OpenAlexW4229053653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.